Sistema de Información Esencial en Terapéutica y Salud

@SIETES7

Última actualización: 19/7/2019
SIETES contiene 92793 citas

 
 
 1 a 20 de 109 siguiente >>
Presentar resultados
Seleccionar todas
3. Cita con resumen
Humphreys K, Maisel NC, Blodgett JC, Fuh IL, Finney JW. Extent and reporting of patient nonenrollment in influential randomized clinical trials, 2002 to 2010. JAMA Intern Med 2013;173:1029-31. [Ref.ID 95615]
4. Cita con resumen
Ferreira ML, Herbert RD, Crowther MJ, Verhagen A, Sutton AJ. When is a further clinical trial justified?. BMJ 2012;345:19. [Ref.ID 94137]
5.Tiene citas relacionadas Cita con resumen
Devanand DP, Mintzer J, Schultz SK, Andrews HF, Sultzer DL, de la Pena D, Gupta S, Colon S, Schimming C, Pelton GH. Relapse risk after discontinuation of risperidone in Alzheimer's disease. N Engl J Med 2012;367:1497-507. [Ref.ID 93889]
6.Tiene citas relacionadas Cita con resumen
Herzig S, Rothberg M. Drug prophylaxis in general medical patients: does usage reflect the benefits and risks?. BMJ 2012;344:21-3. [Ref.ID 93191]
7.Tiene citas relacionadas Cita con resumen
Lewiecki EM, Miller PD, Bilezikian JP. Bone-density testing interval and transition to osteoporosis. N Engl J Med 2012;366:1546. [Ref.ID 92769]
8. Cita con resumen
Archibald K, Coleman R, Foster C, on behalf of 19 other signatories. Open letter to UK Prime Minister David Cameron and Health Secretary Andrew Lansley on safety of medicines. Lancet 2011;377:1915. [Ref.ID 91289]
9. Cita con resumen
Egleston BL, Dunbrack Jr RL, Hall MJ. Clinical trials that explicitly exclude gay and lesbian patients. N Engl J Med 2009;361:1054-5. [Ref.ID 88086]
10. Cita con resumen
Leendertse AJ, Visser D, Egberts ACG, van den Bemt PMLA. The relationship between study characteristics and the prevalence of medication-related hospitalizations: a literature review and novel analysis. Drug Saf 2010;33:233-44. [Ref.ID 88052]
11.Tiene citas relacionadas Cita con resumen
Zwarenstein M, Treweek S, Gagnier JJ, Atlman DG, Tunis S, Haynes B, Oxman AD, Moher D. Improving the reporting of pragmatic trials: an extension of the CONSORT statement. BMJ 2008;337:1223-6. [Ref.ID 84552]
12. Cita con resumen
Eldridge S, Ashby D, Bennett C, Wakelin M, Feder G. Internal and external validity of cluster randomised trials: systematic review of recent trials. BMJ 2008;336:876-80. [Ref.ID 82688]
13.Tiene citas relacionadas Cita con resumen
Kaplan NM. Vascular outcome in type 2 diabetes: an ADVANCE?. Lancet 2007;370:804-5. [Ref.ID 81005]
14.Tiene citas relacionadas Cita con resumen
Fowler RA, Van Spall HGC. Eligibility criteria of randomized controlled trials. In reply. JAMA 2007;298:39-40. [Ref.ID 80529]
15.Tiene citas relacionadas Cita con resumen
Costantino G, Ceriani E, Rusconi E, Montano N. Eligibility criteria of randomized controlled trials. JAMA 2007;298:39. [Ref.ID 80528]
16.Tiene citas relacionadas Cita con resumen
17.Tiene citas relacionadas Cita con resumen
Perel P, Roberts I, Sena E, Wheble P, Briscoe C, Sandercock P, Macleod M, Mignini LE, Jayaram P, Khan KS. Comparison of treatment effects between animal experiments and clinical trials: systematic review. BMJ 2007;334:197-200. [Ref.ID 79011]
18.Tiene citas relacionadas Cita con resumen
Hackam DG. Translating animal research into clinical benefit. BMJ 2007;334:163-4. [Ref.ID 79001]
19.Tiene citas relacionadas Cita con resumen
D'Agostino Jr RB, D'Agostino Sr RB. Estimating treatment effects using observational data. JAMA 2007;297:314-6. [Ref.ID 78932]
Seleccionar todas
 
 1 a 20 de 109 siguiente >>